Induced pluripotent stem cell

Stem cells generated from adult cells

Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka and his team in 2006, for which he was awarded the Nobel Prize in Physiology or Medicine in 2012. This breakthrough has significant implications for regenerative medicine, disease modeling, and drug discovery.

History

The concept of reprogramming adult cells to a pluripotent state was first demonstrated by Yamanaka and his colleagues, who introduced four specific genes encoding transcription factors into adult fibroblasts. These factors, known as the "Yamanaka factors," include Oct4, Sox2, Klf4, and c-Myc. The introduction of these factors reprograms the adult cells into a pluripotent state, similar to that of embryonic stem cells.

Characteristics

File:Stem cell diagram.svg

Diagram of stem cell differentiation.

Induced pluripotent stem cells share many characteristics with embryonic stem cells, including the ability to differentiate into any cell type of the three germ layers: ectoderm, mesoderm, and endoderm. This pluripotency makes them a valuable tool for studying development and disease.

Pluripotency

Pluripotency refers to the ability of a stem cell to differentiate into any cell type of the body. iPSCs exhibit this property, making them a powerful tool for regenerative medicine. They can be used to generate neurons, cardiomyocytes, hepatocytes, and many other cell types.

Self-renewal

Like embryonic stem cells, iPSCs have the ability to self-renew indefinitely in culture. This property allows for the generation of large quantities of cells for research and therapeutic purposes.

Applications

File:Stem cell research.jpg

Stem cell research in a laboratory setting.

The ability to generate patient-specific iPSCs has opened new avenues in personalized medicine. iPSCs can be used to model diseases, screen drugs, and potentially provide autologous cell therapies.

Disease Modeling

By generating iPSCs from patients with specific genetic disorders, researchers can create disease models in vitro. These models help in understanding the pathophysiology of diseases and in identifying potential therapeutic targets.

Drug Discovery

iPSCs provide a platform for high-throughput drug screening. By testing compounds on iPSC-derived cells, researchers can identify drugs that may be effective in treating specific diseases.

Regenerative Medicine

The potential to generate patient-specific cells for transplantation offers a promising avenue for regenerative medicine. iPSCs could be used to replace damaged tissues in conditions such as Parkinson's disease, diabetes, and heart disease.

Challenges

Despite their potential, iPSCs face several challenges. The reprogramming process can introduce genetic and epigenetic abnormalities. Additionally, the use of oncogenes like c-Myc raises concerns about tumorigenicity.

Ethical Considerations

The use of iPSCs circumvents many ethical issues associated with embryonic stem cells, as they do not require the destruction of embryos. However, ethical considerations regarding genetic manipulation and potential clinical applications remain.

Related pages

• Stem cell
• Embryonic stem cell
• Regenerative medicine
• Shinya Yamanaka